Pharmacy Times September 2, 2024
High-cost novel therapies challenge payers and patients, while biosimilars help balance affordability.
The specialty drug market is experiencing unprecedented growth, driven by the rapid development and adoption of innovative therapies.1 In the mid-1990s, fewer than 30 specialty drugs were available, but by 2023, they accounted for over 80% of the 55 novel drugs that were approved.1 By mid-2024, the FDA has already approved 23 novel drug therapies, with specialty drugs now representing about 75% of the approximate 7000 new drugs under development.1,2
This surge highlights the increasing demand for advanced treatments for patients with complex and chronic conditions or rare diseases. However, this growth also presents challenges, including high costs, regulatory complexities, and issues with medication access.
Defining Specialty Drugs...
Today's Sponsors
Today's Sponsor